Table 1.

Clinical Characteristics patients with severe ARDS by COVID-19 where tracheostomy was performed.

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5
Characteristics
Age, yr	68	70	70	63	68
Sex,	F	M	M	M	M
Weight, kg	65	92	75	90	97
Height, cm	165	165	162	176	166
APACHE II score	21	17	21	16	20
PaO2/FiO2 in ICU admission (mmHg)	180	206	92	133	173
PaO2 in ICU admission (mmHg)	80	124	92	106	104
Chronic medical illness
Hypertension	No	Yes	Yes	No	Yes
Diabetes	No	No	No	No	Yes
Chronic obstructive pulmonary disease	Yes	No	No	No	No
Heart disease	No	Yes	Si	No	Yes
Laboratory parameters
Leukocytes count per mL	17980	8400	4800	3450	7400
Lymphocytes count per mL	230	510	180	280	1080
C-reactive protein, mg/L	25	15	5	7	17
D-dimer, ng/mL	4870	707	1900	357	1295
Lactate dehydrogenase, U/L	989	600	248	519	913
Creatine kinase, ng/mL	291	140	33	110	54
Serum Ferritin, μg/L	531	2650	689	2898	653
Interleukin-6, pg/mL	158	85	1819	670	77
Procalcitonin, ng/mL	13,3	0,32	64	0,46	0,22
Triglycerides, mg/dL	127	195	118	256	117
Treatment
Hydroxychloroquine	Yes	Yes	Yes	Yes	Yes
Lopinavir/ritonavir	Yes	Yes	Yes	Yes	Yes
Azithromycin	Yes	Yes	Yes	Yes	Yes
Tocilizumab	No	No	Yes	No	Yes
Glucocorticoids	Yes	Yes	Yes	Yes	Yes
Clinical ICU course
Duration since intubation to tracheostomy (days)	13	27	17	16	16
Length of ICU stay (days)	39	31	38	40	39a
Survival at 21 after PTD	Yes	Yes	No	No	Yes

^aRemained ICU, PTD: percutaneous dilational tracheostomies.